Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952660 · ClinicalTrials.gov registry record · Phase 4
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
A Phase 4 study of Cervical Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06952660: Recruiting Phase 4 study of Cervical Cancer, sponsored by Pfizer.
NCT06952660 is a Phase 4 study of Cervical Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 100 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06952660, a Phase 4 study of Cervical Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.
Conditions Studied
Interventions
- DRUG TIVDAK
Study Locations (20)
Florida
- Mount Sinai Comprehensive Cancer Center - Aventura - Aventura
- Florida Cancer Specialists - Bonita Springs
- Florida Cancer Specialists - Bradenton
- Florida Cancer Specialists - Cape Coral
- Broward Health Coral Springs - Coral Springs
- Florida Cancer Specialists - Daytona Beach
- Broward Health North - Deerfield Beach
- Florida Cancer Specialists - Fleming Island
- Broward Health Imperial Point - Fort Lauderdale
- Broward Health Medical Center - Fort Lauderdale
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Fort Myers
- HCA Mercy Hospital - Miami
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Mount Sinai Medical Center of Florida, Inc - Miami Beach
- Florida Cancer Specialists - N. Venice
- Florida Cancer Specialists - Naples
- Orlando Health Cancer Institute - Orlando
- Orlando Health Orlando Regional Medical Center - Orlando
- Orlando Health Winnie Palmer Hospital for Women & Babies - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2028-12-13 |
| Phase | Phase 4 |
What NCT06952660 shows while recruiting
NCT06952660 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which TIVDAK is the first listed.
NCT06952660 names 20 study sites across 1 states, led by Florida.
Frequently Asked Questions
What is clinical trial NCT06952660 about?
NCT06952660 is a clinical study titled "Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer". TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possib...
What is the current status of trial NCT06952660?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-05-07. Estimated completion is 2028-12-13.
What conditions does trial NCT06952660 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT06952660?
The interventions under investigation include: TIVDAK (DRUG).
Who is sponsoring clinical trial NCT06952660?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952660 being conducted?
This trial has 20 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06952660's enrollment target sits among peer trials
100 70th of 144 higher than 72 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI